- ISIN
- US63009J1079
- CUSIP
- 63009J107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 11, 2020
Highlights
- EPS (TTM)
- -€1.80
- Total Revenue (TTM)
- €47.94M
- Gross Profit (TTM)
- €47.94M
- EBITDA (TTM)
- -€55.82M
- Year Range
- $4.50 - $57.14
- Target Price
- $26.00
- ROA (TTM)
- -125.61%
- ROE (TTM)
- 100.75%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NBTX Performance Chart
Nanobiotix S.A. (NBTX) is up 52.4% since the beginning of the year. At $35 per share, NBTX is trading 38.3% below its 52-week high of $57. Investors who bought $1,000 worth of NBTX shares 5 years ago would now be looking at an investment worth $2,443.
Loading charts...
Returns By Period
Nanobiotix S.A. (NBTX) has returned 52.38% so far this year and 688.14% over the past 12 months.
Nanobiotix S.A.
- 1D
- -2.87%
- 1M
- -14.09%
- YTD
- 52.38%
- 6M
- 53.98%
- 1Y
- 688.14%
- 3Y*
- 85.89%
- 5Y*
- 19.56%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NBTX Monthly Returns History
Based on dividend-adjusted daily data since Dec 11, 2020, NBTX's average daily return is +0.28%, while the average monthly return is +4.03%. At this rate, an investment would double in approximately 1.5 years.
Historically, 46% of months were positive and 54% were negative. The best month was May 2023 with a return of +114.0%, while the worst month was Apr 2023 at -39.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 12 months.
On a daily basis, NBTX closed higher 43% of trading days. The best single day was May 5, 2023 with a return of +229.1%, while the worst single day was Apr 25, 2023 at -40.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.17% | 47.81% | -0.55% | 12.15% | 16.70% | -12.80% | 52.38% | ||||||
| 2025 | 21.43% | 0.72% | 1.99% | -5.31% | 20.94% | 15.37% | 45.98% | 29.55% | 111.18% | 10.48% | -0.86% | 11.74% | 705.57% |
| 2024 | 4.40% | -17.76% | 4.00% | -10.15% | 20.55% | -28.98% | 8.40% | 10.70% | -4.17% | -27.65% | -22.36% | -11.15% | -60.58% |
| 2023 | 16.24% | -17.49% | 0.14% | -39.29% | 114.02% | 10.70% | 52.07% | 18.55% | -4.27% | -22.86% | -16.96% | 29.88% | 98.37% |
| 2022 | -5.56% | -1.44% | -1.33% | -20.70% | -11.36% | -27.34% | -38.95% | 71.98% | -11.28% | 11.86% | -0.25% | -7.09% | -54.69% |
| 2021 | 1.03% | -0.32% | -9.49% | 2.86% | 10.67% | -19.51% | 6.86% | -14.44% | -9.84% | -8.19% | -18.70% | -4.48% | -50.91% |
Benchmark Metrics
Nanobiotix S.A. has an annualized alpha of 72.80%, beta of 1.09, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 11, 2020.
- This stock participated in 119.39% of S&P 500 Index downside but only 114.38% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 72.80%
- Beta
- 1.09
- R²
- 0.02
- Upside Capture
- 114.38%
- Downside Capture
- 119.39%
Return for Risk
Risk / Return Rank
NBTX ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nanobiotix S.A. (NBTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +4.40 | ||
| Sortino ratioReturn per unit of downside risk | +1.56 | ||
| Omega ratioGain probability vs. loss probability | 1.55 | 1.37 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 13.82 | 2.78 | +11.04 |
| Martin ratioReturn relative to average drawdown | 32.01 | 12.44 | +19.57 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nanobiotix S.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nanobiotix S.A. was 89.94%, occurring on May 1, 2023. Recovery took 608 trading sessions.
The current Nanobiotix S.A. drawdown is 36.03%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -89.94%May 2023 | 2y 3mo | 2y 5mo | 4y 8moJan 2021 - Oct 2025 |
2025 bear market2025 | -50.25%Oct 2025 | 13d | 4mo 3d | 4mo 16dOct 2025 - Feb 2026 |
2026 bear market2026 | -39.08%Jun 2026 | 26d | — | 1mo 9dMay 2026 - now |
2026 bear market2026 | -27.66%Mar 2026 | 10d | 1mo 17d | 1mo 27dMar 2026 - May 2026 |
2025 bear market2025 | -21.10%Oct 2025 | 0s | 3d | 3dOct 2025 - Oct 2025 |
Drawdown Indicators
| NBTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.94% | -56.78% | -33.16% |
Max Drawdown (1Y)Largest decline over 1 year | -50.25% | -9.10% | -41.15% |
Max Drawdown (3Y)Largest decline over 3 years | -73.88% | -18.90% | -54.98% |
Max Drawdown (5Y)Largest decline over 5 years | -86.80% | -25.43% | -61.37% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -36.03% | -1.80% | -34.23% |
Average DrawdownAverage peak-to-trough decline | -57.32% | -10.71% | -46.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.66% | 2.03% | +19.63% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nanobiotix S.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nanobiotix S.A. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NBTX relative to other companies in the Biotechnology industry. Currently, NBTX has a P/S ratio of 30.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NBTX
Add Nanobiotix S.A. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NBTX